-+ 0.00%
-+ 0.00%
-+ 0.00%
Eli Lilly Takes 19.9% Stake In TRex Bio With 5.48M Shares, Investing $12.3M In IPO
Share
Listen to the news

The Reporting Person beneficially owns an aggregate of 5,480,872 shares of Common Stock of the Issuer, consisting of (a) 2,510,411 shares of Common Stock that were issued to the Reporting Person upon conversion of Series A redeemable convertible preferred stock, (b) 2,095,461 shares of Common Stock that were issued to the Reporting Person upon conversion of Series B redeemable convertible preferred stock and (c) 875,000 shares of Common Stock purchased by the Reporting Person in the IPO at the public offering price of $14.00 per share, for an aggregate purchase price of approximately $12.3 million. The funds used by the Reporting Person to acquire the Common Stock purchased in the IPO consisted of cash on hand.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending